Skip to main content

Table 5 Description of overall cardiovascular toxicity observed with pazopanib treatment

From: Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Entire Study Population (n)

35

Any CV toxicity

24 (69%)

Any CV toxicity excluding hypertension

12 (34%)

Grade 1 QTc prolongation

6 (17%)

Grade 2 QTc prolongation

2 (6%)

Grade 3 heart failure

1 (3%)

Grade 5 heart failure

1 (3%)

Grade 3 atrial flutter

1 (3%)

Grade 3 peripheral ischemia

1 (3%)

Grade 2 hypertension

3 (9%)

Grade 3 hypertension

17 (49%)

  1. n number, CV cardiovascular, QTc corrected QT interval. Refer to Table 1 for grading definitions. Results displayed as number of patients (% of all study patients)
Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us